Whoa, whoa, whoa....let's not get too hasty here...you see the cooking process vaporizes all the fetal cells, so it's kosher...
I'll see myself out....
![Bag :bag:](./images/smilies/bag.gif)
Whoa, whoa, whoa....let's not get too hasty here...you see the cooking process vaporizes all the fetal cells, so it's kosher...
Sorry, I'm not sure what your sentence means. There's no "guarantee" of anything which I guess is why you used scare quotes?
Mm. Not sure about that, I hear conflicting views and I suspect these measures are not reliable numbers (observational data i from the general population is much less robust than trials data).Also too I understand that the Pfizer shot is seriously less effective against the Delta variant. All the reason to offer a booster to the first recipients. I guess once there is a fast, easy and cheap way to evaluate the remaining protection the boost can get applied selectively.
Mild cases of COVID-19 among vaccinated individuals are becoming increasingly common as the highly contagious delta variant barrels through communities, but physicians and public health experts say that shouldn’t be a cause for significant concern.
A breakthrough case of COVID-19 occurs when a person contracts COVID-19 at least two full weeks after the final dose of the vaccine. The Centers for Disease Control and Prevention tracks only breakthrough cases that result in hospitalization or death, as these incidences are both serious and very rare.
COVID-19 cases are up to five times more common in unvaccinated individuals compared with the vaccinated, according to the CDC. But state-level data shows that milder breakthrough cases that do not result in hospitalization are on the rise among the fully vaccinated as virus transmission increases and vaccine efficacy decreases. And they’re expected to keep increasing.
“It’s likely that everybody will probably get infected with COVID-19 [at some point] because it’s an endemic respiratory virus. The goal is to make sure that at that time, that infection occurs after you’ve been vaccinated so it’s mild,” said Amesh Adalja, a doctor and infectious disease specialist at Johns Hopkins Center for Health Security.
That seems highly plausible: there's so much of the virus around that eradication, even at a local level, is not possible. There will always be reservoirs to supply reintroduction.AndyinPA wrote: ↑Thu Sep 23, 2021 12:33 am https://www.rollcall.com/2021/09/22/bre ... ng-months/
“It’s likely that everybody will probably get infected with COVID-19 [at some point] because it’s an endemic respiratory virus. The goal is to make sure that at that time, that infection occurs after you’ve been vaccinated so it’s mild,” said Amesh Adalja, a doctor and infectious disease specialist at Johns Hopkins Center for Health Security.
Sam the Centipede wrote: ↑Thu Sep 23, 2021 5:49 am![]()
So the big epidemiological question must be: how often will "mild cases" (which could mean feeling awful for several days and not feel at all "mild" to the victim) result in Long Covid with permanent damage?
Flu victims can often be sub-par for weeks or months afterwards nominal recovery, and that's going to happen with Covid, but it's the permanent damage that's most worrying.
https://www.mayoclinic.org/diseases-con ... t-20490351Most people who have coronavirus disease 2019 (COVID-19) recover completely within a few weeks. But some people — even those who had mild versions of the disease — continue to experience symptoms after their initial recovery.
These people sometimes describe themselves as "long haulers" and the conditions have been called post-COVID-19 syndrome or "long COVID-19." These health issues are sometimes called post-COVID-19 conditions. They're generally considered to be effects of COVID-19 that persist for more than four weeks after you've been diagnosed with the COVID-19 virus.
![]()
Much is still unknown about how COVID-19 will affect people over time, but research is ongoing. Researchers recommend that doctors closely monitor people who have had COVID-19 to see how their organs are functioning after recovery.
in an intro to the written interview:GoogleTranslate wrote:Stéphane Bancel on the pandemic
Moderna boss expects the corona pandemic to end in a year
Today, 7:16 am
Stéphane Bancel, CEO of the US biotechnology group, expects the corona pandemic to end in a year.
Older people as well as high-risk patients who were vaccinated at the beginning of the pandemic should now receive booster vaccinations.
According to Bancel, there will be enough doses by the middle of next year to vaccinate everyone in the world. From then on, Covid-19 will become normal flu.
The mRNA technology has huge potential, said Bancel to the "Blick". He has in mind, for example, that Covid-19 could be part of a combined vaccination with which one could be vaccinated against all respiratory viruses. Vaccination combinations against the coronavirus and flu viruses should also be possible, so that patients are vaccinated against several viruses.
Moderna will start the clinical trial for these vaccines before the end of this year, while the one for the flu vaccine is already underway. These combined vaccines are expected to hit the market in 2023.
The Moderna CEO replies to vaccine skeptics that their fear is unfounded. Clinical studies have clearly shown that the new technology does not interfere with the DNA. The mRNA vaccine consists of four nucleic acids that are biodegradable. Two hours after the vaccination, the lipid nanoparticles are no longer detectable.
original in German https://www.srf.ch/news/international/s ... einem-jahr
German wrote: Wie oft werden künftig Auffrischimpfungen gegen das Coronavirus nötig sein? Für Jüngere alle drei Jahre, für Ältere jedes Jahr, vermutet der Chef des Unternehmens Moderna, Stéphane Bancel.
Google Translate wrote:How often will booster vaccinations against the coronavirus be necessary in the future? For younger people every three years, for older people every year, suspects the boss of the Moderna company, Stéphane Bancel.
Why Covid could become like the common cold — or not
Tom Whipple, Science Editor
Thursday September 23 2021, 10.30am BST, The Times
If the virus had a plan, it would not be to kill you. If this scrap of protein and nucleic acid could control its destiny it would want you sneezing and sniffling and superspreading indefinitely — something that is notoriously hard to do from a morgue.
Last night Dame Sarah Gilbert, the creator of the Oxford-AstraZeneca vaccine, said that, ultimately, this would be what the coronavirus would achieve.
“We already live with four different human coronaviruses that we don’t really ever think about very much and eventually Sars-CoV-2 will become one of those,” she said.
paywall https://www.thetimes.co.uk/article/why- ... -w75kl88cm
There is another factor in this: the general level of immunity in the population. I don't mean "herd immunity", which is a specific epidemiological concept (when a large enough fraction of the population is immune so the reproduction number R is less than 1.0 and an outbreak will not become an epidemic, even without extra mitigating measures).RTH10260 wrote: ↑Thu Sep 23, 2021 7:56 am similar predictionWhy Covid could become like the common cold — or not
![]()
Last night Dame Sarah Gilbert, the creator of the Oxford-AstraZeneca vaccine, said that, ultimately, this would be what the coronavirus would achieve.
“We already live with four different human coronaviruses that we don’t really ever think about very much and eventually Sars-CoV-2 will become one of those,” she said.
Well that and babies are being born today with antibodies...Sam the Centipede wrote: ↑Thu Sep 23, 2021 4:36 pmThere is another factor in this: the general level of immunity in the population. I don't mean "herd immunity", which is a specific epidemiological concept (when a large enough fraction of the population is immune so the reproduction number R is less than 1.0 and an outbreak will not become an epidemic, even without extra mitigating measures).RTH10260 wrote: ↑Thu Sep 23, 2021 7:56 am similar predictionWhy Covid could become like the common cold — or not
![]()
Last night Dame Sarah Gilbert, the creator of the Oxford-AstraZeneca vaccine, said that, ultimately, this would be what the coronavirus would achieve.
“We already live with four different human coronaviruses that we don’t really ever think about very much and eventually Sars-CoV-2 will become one of those,” she said.
Consider young kids growing up now. With SARS-CoV-2 ubiquitous they are liable to be exposed early in life and experience only mild illness, whether vaccinated or not. Each few years, or more frequently, they will be exposed again during normal social and family interactions. They might become ill, or they might extinguish the infection before symptoms appear. In either case, the immune system will identify the threat and respond. Part of that response is a strengthening of immunity (more antibodies, more memory cells) — in other words, a natural booster.
A constantly refreshing immune memory could make it similar a common cold to most victims … if we're lucky!!
That's a way off, vaccination is still the best option.
https://news.weill.cornell.edu/news/202 ... eir-babiesThey also assessed the presence of antibodies in the cord blood of babies born to these women at the time of birth. The research demonstrated that 99 percent of newborns had protective antibodies after their mothers received both vaccine doses, and 44 percent of babies had antibodies after one dose
There are very specific, well-documented reasons that Americans are hesitant to take vaccines. They vary from the troubling way the medical system treats people of color, to vaccine misinformation campaigns overwhelmingly popular in conservative circles, to logistical challenges.
But population health researchers, whose work considers how society as a whole is fairing, said low vaccine uptake may be looked at another way: as the predictable outcome of a campaign subject to entrenched social forces that have diminished American health and life expectancy since the 1980s.
![]()
Woolf calls this “breakthrough without follow-through”. In that light, the plodding vaccination campaign could be seen as one more aspect of the American “health disadvantage”.
The phrase describes a paradox: the US houses among the most advanced medical and research centers in the world, but performs poorly in basic health metrics such as maternal mortality and infant mortality; accidental injury, death and disability; and chronic and infectious disease.
“So much of the whole issue of social determinants of health and the US ‘health disadvantage’ is rooted in a lack of trust and a lack of trustworthiness in many parts of our society,” said Laudan Y Aron, a senior fellow at the Urban Institute’s health policy center.
Covid: Merck’s antiviral pill molnupiravir slashes chances of illness and death
Tom Whipple, Science Editor
Friday October 01 2021, 12.25pm BST, The Times
An antiviral pill cuts the risk of needing hospital treatment from Covid-19 in half and slashes the chance of dying, according to landmark findings that promise to bring the world closer to normality.
The potentially game-changing results offer the promise of a completely new way of treating the disease, and represent what scientists hope will be the first of many successful antivirals.
Until now, the only way of treating the disease was with steroids, such as dexamethasone and intravenous antibodies. Both are used in patients who are already very sick.
The new treatment, molnupiravir, created by the pharmaceutical companies Merck and Ridgeback Biotherapeutics, targets the virus’s life cycle, interfering with its replication by introducing errors in its genome.
paywall https://www.thetimes.co.uk/article/covi ... -vgx2m53v7
Merck to seek emergency authorization for oral Covid treatment after ‘compelling results’ in trials
PUBLISHED FRI, OCT 1 20216:01 AM EDT UPDATED
Chloe Taylor
KEY POINTSMerck and Ridgeback Biotherapeutics plan to seek emergency authorization for their oral antiviral treatment for Covid, after the medicine showed “compelling results” in clinical trials.
- A phase 3 trial of Merck and Ridgeback Biotherapeutics’ oral antiviral treatment molnupiravir showed it reduced the risk of hospitalization or death by around 50% in Covid patients.
Merck plans to seek emergency use authorization in the U.S. and submit marketing applications to other global drug regulators.
If authorized by regulatory bodies, molnupiravir could be the first oral antiviral medicine for Covid.
The drug, molnupiravir, reduced the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid, the companies announced Friday. Molnupiravir is administered orally and works by inhibiting the replication of the coronavirus inside the body.
An interim analysis of a phase 3 study found that 7.3% of patients treated with molnupiravir were hospitalized within 29 days. Of the patients who received a placebo, 14.1% were hospitalized or died by day 29. No deaths were reported in patients who were given molnupiravir within the 29-day period, while eight deaths were reported in placebo-treated patients.
All 775 trial participants had laboratory-confirmed symptomatic Covid-19 and were randomly given molnupiravir or a placebo within five days of symptoms.
Every participant was unvaccinated and had at least one underlying factor that put them at greater risk of developing a more severe case of the virus. The most common risk factors included obesity, being over age 60 and having diabetes or heart disease.
https://www.cnbc.com/2021/10/01/merck-t ... tment.html
Spurious comma?Until now, the only way of treating the disease was with steroids, such as dexamethasone and intravenous antibodies.